April 26, 2018 / 4:39 PM / in a month

BRIEF-Transgene Q1 Operating Revenue Stable At 1.8 Million Euros

April 26 (Reuters) - Transgene SA:

* TRANSGENE: €35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018

* CLINICAL TRIALS NOW ON-GOING WITH 5 IMMUNO-THERAPEUTICS

* CLINICAL READOUTS EXPECTED FOR EACH OF OUR 5 PRODUCTS IN 2018

* Q1 OPERATING REVENUE EUR 1.8 MILLION VERSUS EUR 1.9 MILLION YEAR AGO

* TRANSGENE EXPECTS ITS CASH BURN FOR 2018 TO BE COMPARABLE TO 2017

* TRANSGENE CONFIRMS THAT IT EXPECTS READOUTS IN 2018 FOR EACH OF ITS 5 PRODUCTS IN CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below